336 related articles for article (PubMed ID: 16757611)
41. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples.
Martínez SB; Palomares JC; Artura A; Parra M; Cabezas JL; Romo JM; Martín-Mazuelos E
J Virol Methods; 2012 Mar; 180(1-2):7-10. PubMed ID: 22197189
[TBL] [Abstract][Full Text] [Related]
42. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology.
Daponte A; Pournaras S; Mademtzis I; Hadjichristodoulou C; Kostopoulou E; Maniatis AN; Messinis IE
J Clin Virol; 2006 Jul; 36(3):189-93. PubMed ID: 16690350
[TBL] [Abstract][Full Text] [Related]
44. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
46. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
47. Performance of the New INNO-LiPA HPV extra to genotype human papillomavirus in cervical cell specimens.
Galan-Sanchez F; Hernández-Menendez M; De Los Rios Hernandez MA; Rodriguez-Iglesias M
Acta Cytol; 2011; 55(4):341-3. PubMed ID: 21791903
[TBL] [Abstract][Full Text] [Related]
48. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
49. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method.
Davis-Devine S; Day SJ; Freund GG
Am J Clin Pathol; 2005 Jul; 124(1):24-30. PubMed ID: 15923167
[TBL] [Abstract][Full Text] [Related]
50. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
Yu S; Kwon MJ; Lee EH; Park H; Woo HY
J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
[TBL] [Abstract][Full Text] [Related]
51. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
52. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
53. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.
Gravitt PE; Schiffman M; Solomon D; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1248-54. PubMed ID: 18483347
[TBL] [Abstract][Full Text] [Related]
54. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
Dockter J; Schroder A; Hill C; Guzenski L; Monsonego J; Giachetti C
J Clin Virol; 2009 Jul; 45 Suppl 1():S55-61. PubMed ID: 19651370
[TBL] [Abstract][Full Text] [Related]
55. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test.
van Hamont D; van Ham MA; Bakkers JM; Massuger LF; Melchers WJ
J Clin Microbiol; 2006 Sep; 44(9):3122-9. PubMed ID: 16954236
[TBL] [Abstract][Full Text] [Related]
57. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the human papillomavirus mRNA test for the detection of cervical lesions in Japan.
Nakayama Y; Yamada M; Kurata A; Kiseki H; Isaka K; Kuroda M
Eur J Gynaecol Oncol; 2015; 36(2):192-6. PubMed ID: 26050359
[TBL] [Abstract][Full Text] [Related]
59. [Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and Amplicor HPV].
Hantz S; Caly H; Decroisette E; Dutrop A; Bakeland D; Pascal B; Darreye G; Dussartre C; Renaudie J; Rogez S; Aubard Y; Denis F; Alain S
Pathol Biol (Paris); 2008 Feb; 56(1):29-35. PubMed ID: 18178026
[TBL] [Abstract][Full Text] [Related]
60. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia.
Holladay EB; Logan S; Arnold J; Knesel B; Smith GD
Cancer; 2006 Dec; 108(6):451-61. PubMed ID: 17078096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
